Britain's pharmaceutical deal with the US forces taxpayers to fork over an extra 3 billion while the NHS budget for medicines balloons from 9.5% to 12%. The agreement raises drug prices by 25% and weakens cost-effectiveness standards that previously protected patients from overpriced treatments, all to appease Trump's demands that Europe subsidize American pharmaceutical profits.